<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>00840140712803</udiDi>
    <basicUdiDi>B-00840140712803</basicUdiDi>
    <tradeName>S-100</tradeName>
    <deviceName>S-100</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2055ML</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:43:14.165Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712797</udiDi>
    <basicUdiDi>B-00840140712797</basicUdiDi>
    <tradeName>RCC</tradeName>
    <deviceName>RCC</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2256MP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:43:10.164Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712780</udiDi>
    <basicUdiDi>B-00840140712780</basicUdiDi>
    <tradeName>RCC</tradeName>
    <deviceName>RCC</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2256MT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:43:09.500Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712773</udiDi>
    <basicUdiDi>B-00840140712773</basicUdiDi>
    <tradeName>RCC</tradeName>
    <deviceName>RCC</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2256MS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:43:08.695Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712766</udiDi>
    <basicUdiDi>B-00840140712766</basicUdiDi>
    <tradeName>RCC</tradeName>
    <deviceName>RCC</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2256ML</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:43:07.764Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712551</udiDi>
    <basicUdiDi>B-00840140712551</basicUdiDi>
    <tradeName>Prostein (P501S)</tradeName>
    <deviceName>Prostein (P501S)</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2006RP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:43:05.058Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712544</udiDi>
    <basicUdiDi>B-00840140712544</basicUdiDi>
    <tradeName>Prostein (P501S)</tradeName>
    <deviceName>Prostein (P501S)</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2006RT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:43:03.011Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712537</udiDi>
    <basicUdiDi>B-00840140712537</basicUdiDi>
    <tradeName>Prostein (P501S)</tradeName>
    <deviceName>Prostein (P501S)</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2006RS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:43:02.811Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712520</udiDi>
    <basicUdiDi>B-00840140712520</basicUdiDi>
    <tradeName>Prostein (P501S)</tradeName>
    <deviceName>Prostein (P501S)</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2006RL</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:43:01.358Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712513</udiDi>
    <basicUdiDi>B-00840140712513</basicUdiDi>
    <tradeName>Prolactin</tradeName>
    <deviceName>Prolactin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2523MP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:42:57.353Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712506</udiDi>
    <basicUdiDi>B-00840140712506</basicUdiDi>
    <tradeName>Prolactin</tradeName>
    <deviceName>Prolactin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2523MT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:42:56.574Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712490</udiDi>
    <basicUdiDi>B-00840140712490</basicUdiDi>
    <tradeName>Prolactin</tradeName>
    <deviceName>Prolactin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2523MS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:42:55.769Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712483</udiDi>
    <basicUdiDi>B-00840140712483</basicUdiDi>
    <tradeName>Prolactin</tradeName>
    <deviceName>Prolactin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2523ML</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:42:54.959Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712438</udiDi>
    <basicUdiDi>B-00840140712438</basicUdiDi>
    <tradeName>PR</tradeName>
    <deviceName>PR</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2023RP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:42:50.956Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712421</udiDi>
    <basicUdiDi>B-00840140712421</basicUdiDi>
    <tradeName>PR</tradeName>
    <deviceName>PR</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2023RT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:42:50.152Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712414</udiDi>
    <basicUdiDi>B-00840140712414</basicUdiDi>
    <tradeName>PR</tradeName>
    <deviceName>PR</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2023RS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:42:49.352Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712407</udiDi>
    <basicUdiDi>B-00840140712407</basicUdiDi>
    <tradeName>PR</tradeName>
    <deviceName>PR</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2023RL</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:42:48.551Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712377</udiDi>
    <basicUdiDi>B-00840140712377</basicUdiDi>
    <tradeName>Podoplanin</tradeName>
    <deviceName>Podoplanin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2338MS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:42:31.562Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712360</udiDi>
    <basicUdiDi>B-00840140712360</basicUdiDi>
    <tradeName>Podoplanin</tradeName>
    <deviceName>Podoplanin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2338ML</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:42:31.043Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140712353</udiDi>
    <basicUdiDi>B-00840140712353</basicUdiDi>
    <tradeName>Podoplanin</tradeName>
    <deviceName>Podoplanin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2097MP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:42:29.962Z</lastUpdated>
  </row>
</eudamedExport>